Apinya Vutikullird, MD

Ark Clinical Research
Long Beach, California, United States

Disclosure information not submitted.

Presentation(s):

• 230 - A Novel SARS-CoV-2 mRNA Virus-Like Particle Vaccine is Highly Potent and Well Tolerated in Adults in a Phase I Randomized Clinical Trial

  Monday, October 20, 2025
  3:15 PM - 3:27 PM US ET